Latest ArticlesSmall interfering RNA(siRNA), a representative therapeutic tool for targeted therapy and precision medicine, can silence the expression of any disease-related gene through sequence-specific RNA interference(RNAi). However, its therapeutic prospects have historically been limited by short half-lives in vivo, difficulties in delivery, and safety concerns. Non-viral vector drug delivery has efficiently achieved siRNA delivery in vivo and silenced the target gene, becoming a successful strategy to overcome above limitations. Currently, several drugs are already in clinical trials, and four new siRNA-based therapies have been approved recently by the U.S. FDA, marking the beginning of a new era of targeted therapies. This review summarizes the recent development and application of siRNA-based non-viral vector delivery strategies and predicts the future development trend of siRNA drug research.
Gene therapy is a new approach to treating diseases by altering gene expression in vivo, provides a new treatment strategy for tumors, rare diseases, and other refractory diseases. Gene therapy modifies the pathogenic genes of an individual through gene editing technology and relies on gene delivery vectors to improve the stability and targeting in vivo of genes. This review briefly describes gene therapy methods, introduces the development of viral and non-viral vectors for gene delivery and gene editing technologies in gene therapy combined with the current gene therapy products, and summarizes the safety issues of gene therapy in clinical practice.
Selenium is one of the elements needed to sustain the normal physiological functions of the human organism. Moderate intake has a variety of functions, including antitumor, antioxidant, and immunological enhancement. Numerous probiotics are capable of converting inorganic selenium into organic selenium and selenium nanoparticles(SeNPs), which can reduce selenium toxicity and increase human absorption. With the dual effects of selenium and probiotics, selenium-enriched probiotics have significant effects on human health and have a broad marketing potential in the development of food and drugs. This review focuses on the fundamental research on the fermentation and bioactivity of selenium-enriched probiotics in recent years and introduces some of the current critical research on selenium-enriched probiotics.
Traditional therapeutic drugs have many shortcomings, such as poor stability, low uptake efficiency, high cytotoxicity and poor targeting ability. Therefore, safe drug delivery systems are needed to prolong drug circulation and exposure in vivo. New drug delivery systems based on red blood cells have gradually become ideal platforms for drug delivery due to their good biocompatibility, low immunogenicity and long circulation time. There are various types of drug delivery systems based on red blood cells, such as red blood cell membrane-encapsulated nanoparticle drug delivery systems and genetically engineered red blood cells. In addition, the functional modification of red blood cells can significantly enhance the targeting of red blood cell-based drug delivery systems to further develop and expand their applications in the treatment of various diseases. This review introduces the delivery methods of chemical drugs and vaccines using red blood cell-based carriers, focuses on bionic nano drug delivery systems and their targeting properties to various body positions. And the research progress of genetically engineered red blood cell-based strategy in recent years is summarized.
Hydrogel is a three-dimensional network polymer with good hydrophilic, flexible and swelling properties. Due to its good drug-loading property, hydrogel is widely used in the fields such as drug delivery, diagnosis, treatment, and tissue engineering. This paper reviews the classification of hydrogels, materials and performance improvement of hydrogels, the formation mechanism of hydrogels and cross-linking agents, by summarizing the recent literature on hydrogels at home and abroad. The development of hydrogels for drug delivery system is prospected. It is expected to provide some references for relevant researches.
Florfenicol is a kind of veterinary chloramphenicol broad-spectrum antibacterial drug, which is widely used in countries around the world due to its strong antibacterial ability. Since the molecular structure of florfenicol contains two chiral centers, the existing synthetic methods can be divided into chiral resolution and asymmetric synthesis. Chiral resolution is relatively unexpensive and has been industrialized, while asymmetric synthesis is greener and in line with the future development trend, but it is challenging. In this paper, the synthesis methods of florfenicol and its key intermediates are reviewed. The preparation methods of D-threo-p-methylsulfonylphenylserine ethyl ester, an intermediate of florfenicol, are described in detail, and different preparation methods including fluorination process are compared.
The related substance Ⅰ was detected by HPLC in midazolam, and it was found that the related substance Ⅰ gradually transformed into the related substance Ⅱ in the injection. According to the relative molecular weight determined by LC/MS, it was speculated that the related substance Ⅰ should be 8-chloro-4-ethoxy-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine, and the related substance Ⅱ should be 1-[4-chloro-2-(2-fluorobenzoyl)phenyl]-2-methyl-1H-imidazole-5-carbaldehyde. This discovery was reported unprecedentedly. These two compounds were synthesized with midazolam as the starting material. Their structures had been confirmed by ESI-HRMS, IR and NMR. The prepared compounds were in consistence with the related substances Ⅰ and Ⅱ in the midazolam bulk drug and its injection by HPLC.
In order to perform the quality control of ursodeoxycholic acid, seven related substances were synthesized. 3,7-Dioxocholanoic acid, 7α-hydroxy-3-oxocholanoic acid, 7-oxolithocholic acid, 3-hydroxy-6-oxocholanoic acid, 3,6-dioxocholanoic acid, 3-oxocholanoic acid and 3β,7α-dihydroxycholanoic acid were synthesized from chenodeoxycholic acid, hyodeoxycholic acid, or lithocholic acid via oxidation, esterification, acylation and reduction. The yields were 68%, 17%, 74%, 60%, 76%, 70% and 15%, respectively. The chemical structures of above related substances were confirmed by NMR and HRMS.
Suzuki-Miyaura coupling reaction was applied to synthesize the related substances of salbutamol sulfate for the first time. Three related substances, namely 4-(2-t-butylamino-1-hydroxyethyl)phenol(related substance B), 2,2'-dihydroxy-4,4'-di(1-hydroxy-2-t-butylaminoethyl)diphenyl ether(related substance F) and 4-(2-t-butylamino-1-hydroxyethyl)-2-methoxymethyl phenol(related substance M), were synthesized through benzyl protection, Suzuki-Miyaura coupling reaction, addition reaction, nucleophilic substitution, Pd/C reduction with 5-bromo-2-hydroxybenzyl alcohol and p-bromophenol as the starting materials. The above method possesses the advantages of generality and high efficiency. The structures of related substances B, F and M were confirmed by HRMS, 1H NMR and 13C NMR.
The establishment of the fibroblast growth factor 21(FGF21)-Fc fusion protein in vitro activity test can be divided into binding assay at the protein level and biological assay at the cell level. This study established a homogeneous time-resolved fluorescence(HTRF) method to detect the binding activity of FGF21-Fc fusion protein and β-Klotho ligand protein. And the reporter gene cells were constructed independently to test biological activity. When the FGF21-Fc fusion protein binded with β-Klotho, the FGF receptor and the intracellular signal transduction were activated to further affect luciferase activity, which could be used to monitor and quantitatively measure biological activity indirectly. During the establishment process of the binding assay, the sample and ligand concentrations, dilution ratios of donor and acceptor, and incubation time were optimized comprehensively. And methodological verification was carried out to prove that the HTRF technology had good repeatability and specificity and this method could be used to detect the binding activity of FGF21-Fc fusion protein and β-Klotho. Later, the fetal bovine serum concentration, density of report gene cells, plate type, and cells in the plate form in bioactivity assay were optimized. And methodological verification was carried out to prove that the reporter gene method had good repeatability and specificity and this method could be used to test the biological activity of FGF21-Fc fusion protein. In this study, a quality control method for FGF21-Fc fusion protein was established, which provided a reference for analysis technology of drugs with the same activity detection difficulties, filling the gap at home and abroad.